In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

CVRx's Series E brings in $84mm

05 Aug 2008

Executive Summary

CVRx Inc. (developing the Rheos system to control hypertension) has raised $84mm through the closing of its Series E venture round. New Enterprise Associates and Johnson & Johnson Development Corp. co-led the financing and were joined by current backers BBT Fund, Thomas Weisel Healthcare Venture Partners, InterWest Partners, Frazier Healthcare Ventures, and SightLine Partners. The company will use the funds to continue its pivotal trial to gain FDA approval for the Rheos device (it is already CE Marked in Europe) and to build a sales and marketing team prior to launching the product. CVRx has raised over $209mm since it was formed in 2001.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By